In 2015
Introduction
The UK Renal Registry (UKRR) collects routine biochemical data from clinical information systems in renal centres in England, Wales and Northern Ireland and receives data from Scotland via the Scottish Renal Registry. Annual cross-sectional analyses are undertaken on some of these variables to determine centre level performance against national (Renal Association (RA)) clinical performance measures [1] . This enables UK renal centres to compare their own performance against each other and to the UK average performance. International chronic kidney disease -mineral bone disorder (CKD-MBD) guidelines were published in 2009 [2] and this prompted changes in CKD-MBD guidelines around the world. Therefore a review of the 5th edition of the RA guidelines was undertaken in order to outline the UK response. These updated RA guidelines were one of the first published by the RA in the 6th edition of their guidelines in March 2015 [3] . Data from 2015 are reported in this chapter, from quarters 2-4, immediately after these updated guidelines were published. The updated RA guidelines offer two audit measures, firstly the proportion of patients with serum phosphate ,1.7 mmol/L and secondly the proportion of patients with all bone parameters within target range. The target range for phosphate recommended in the guideline is 1.1-1.7 mmol/L (not ,1.7 mmol/L as for the phosphate audit measure). Therefore the authors have interpreted the latter audit measure to include this recommended target range for phosphate of 1.1-1.7 mmol/L which results in different measures of phosphate being used at different points in the chapter and readers should be aware of this when interpreting these results.
Audit measures for kidney disease increasingly include tighter specification limits in conjunction with a growing evidence base. Out of range observations (e.g. hyperphosphataemia or PTH below target range) need to be interpreted cautiously as they may relate to different clinical problems or population characteristics. These will therefore require different strategies to improve centre performance of clinical audit measures. Summary statistical data have been provided to enhance understanding of the population characteristics of each centre and longitudinal analyses to demonstrate changes over time.
Data are also available on the UKRR data portal at www.renalreg.org. Table 8 .1 lists the recommended biochemical based audit measures from the RA which are relevant to the dialysis population. Several of the audit measures are not currently reported by the UKRR in its annual report; the reasons behind this are varied, but predominantly relate to a high proportion of incomplete data or the relevant variable not being within the specified UKRR dataset. The UKRR is actively working with renal centres to collect more granular and wide ranging data using new methods of data collection.
Methods
The analyses presented in this chapter relate to biochemical variables in the prevalent dialysis cohort in the UK. The cohort studied were patients prevalent on dialysis treatment on 31st December 2015. Patients receiving dialysis for less than 90 days and those who had changed modality or renal centre in the last 90 days were excluded. Haemodialysis (HD) and peritoneal dialysis (PD) cohorts were analysed separately. A full definition of the cohort including inclusion and exclusion criteria is available in appendix B (www.renalreg.org).
The biochemical variables analysed in this chapter were serum phosphate, calcium (adjusted for albumin), PTH and bicarbonate. The method of data collection and validation by the UKRR has been previously described [4] . In brief, for each quarter of 2015 the UKRR extracted biochemical data electronically from clinical information systems in renal centres in England, Wales and Northern Ireland (E,W&NI). Cambridge renal centre (Addenbrooke's) was not able to submit the 2015 data at patient level on time for the end of 2015 data collection period. Scottish centres have only been included in analyses relating to corrected calcium and phosphate control, with data for their prevalent dialysis cohort being supplied directly by the Scottish Renal Registry. The UKRR does not currently collect data regarding different assay methods mainly because a single dialysis centre may process samples in several different laboratories. The audit measure used for serum phosphate was ,1.7 mmol/L in both the HD and PD cohorts [1, 3] . However, for the audit measure of composite control of bone parameters it is recommended that all parameters are within the target range and this includes phosphate within the range of 1.1-1.7 mmol/L, so two different phosphate measures are in use in this report. For centres providing adjusted calcium values, these data were analysed directly as it is these values on which clinical decisions within centres are based. For centres providing unadjusted calcium values, a formula in widespread use was used to calculate adjusted calcium [5] . The audit measure for adjusted calcium depends on the local reference range [3] . For the purposes of these analyses, the UKRR has used the RA guideline standard of adjusted calcium between 2.2-2.5 mmol/L as the audit measure [3] . There are also a variety of methods and reference ranges in use to measure PTH. To enable some form of comparative audit the UKRR has used two to nine times the median upper limit of the reference range (8 pmol/L) as the audit measure in line with the RA clinical practice guidelines and KDIGO 2009 guidance [2, 3] . This equates to a PTH range of 16-72 pmol/L. The audit measure used for serum bicarbonate in the HD cohort was 18-24 mmol/L as per the updated HD guidelines and in the PD cohort was 22-30 mmol/L. A summary of the current RA audit measures for these variables and conversion factors to SI units are given in table 8.2 .
Quarterly values were extracted from the database for the last two quarters for calcium, phosphate and bicarbonate and the last three quarters for PTH. Patients who did not have these data were excluded from the analyses. Data completeness was analysed at centre and country level. All patients were included in analyses but centres with less than 50% completeness were excluded from plots and tables showing centre level performance. Data were also excluded from plots and tables when there were fewer than 10 patients with data, both at centre or country level. These data were analysed to calculate summary descriptive The UKRR has reported summary statistics for total cholesterol. These summary data were presented on 2013 data and will be presented again on 2016 data. Reliable information is not currently available within the UKRR data on statin prescription statistics (maximum, minimum, means with the corresponding standard deviation, medians and interquartile ranges). Where applicable, the percentage achieving the Renal Association standard or other surrogate clinical performance measure was also calculated.
The simultaneous control of all three components of bone and mineral disorder (BMD) parameters were analysed in combination. The proportion of patients with control of none, one, two or three parameters are presented. For the purpose of these analyses an adjusted calcium between 2.2-2.5 mmol/L, a phosphate level being maintained between 1.1-1.7 mmol/L and a PTH level between two and nine times the upper limit of normal (i.e. 16-72 pmol/L), were evaluated in combination.
Centres report several biochemical variables with different levels of accuracy, leading to problems in comparative evaluation. For example, in the case of serum bicarbonate, data can be submitted as integer values but some centres submit data to one decimal place. All data have been rounded in an attempt to make centres more comparable.
The number preceding the centre name in each figure indicates the percentage of missing data for that centre. Funnel plot analyses were used to identify outlying centres [6] . The percentage within range for each standard was plotted against centre size along with the upper and lower 95% and 99.9% limits. Centres can be identified on these plots by looking up the number of patients treated in each centre in the relevant table and finding this value on the x-axis. Longitudinal analyses were performed for some data to calculate overall changes in achievement of a performance measure annually from 2005 to 2015 and were recalculated for each previous year using the rounding procedure.
All data are presented unadjusted for case-mix.
Results

Mineral and bone variables Phosphate
In 2015 the following Renal Association clinical practice guideline regarding phosphate management was applicable: Overall, data from 22,081 HD and 3,002 PD patients across the UK were included in the analyses of serum Methven/Perisanidou/Nicholas/Dawnay For those receiving HD, 64.1% of patients achieved a phosphate level below 1.7 mmol/L, the audit measure specified by the RA, and for those on PD this was 60.5% (tables 8.4, 8.6 ).
There was inter-centre and inter-modality variation in the proportion of patients below and equal to or above the phosphate target specified by the clinical performance audit measure (figures 8.1-8.4, tables 8.4, 8.6 ).
Funnel plots for HD patients with controlled phosphataemia (,1.7 mmol/L), show a number of centres attaining this standard in a significantly high proportion of patients: London West, Birmingham QEH, London Kings, Nottingham, Dorset, Wrexham, York and Liverpool Aintree. All these centres achieved above the 99.9% upper confidence interval following correction for centre size. In addition, a number of centres had achieved the serum phosphate control standard in a lower than expected proportion of patients (being below the lower 99.9% confidence interval): Portsmouth, Glasgow, Kent, Edinburgh and Dundee (figure 8.2).
Funnel plots for PD patients indicated that the control of phosphate levels were similar in all centres. No significant outliers were identified (figure 8.4). Methven/Perisanidou/Nicholas/Dawnay The audit measure of phosphate ,1.7 mmol/L is new in the updated 2015 clinical practice guideline [3] and comparable data for previous years have been calculated for comparison purposes. Longitudinal analysis demonstrated a small but continued improvement against the clinical performance measure for those receiving HD whilst the proportion of PD patients with hyperphosphataemia has remained stable (figure 8.5). Data showing the performance of centres in attaining phosphate control within the guideline target range (1.1-1.7 mmol/L) can be found in appendix 1 of this chapter (rather than the audit measure of ,1.7 mmol/L presented here).
Simultaneous control of adjusted calcium, phosphate and PTH in preventing severe hyperparathyroidism At the beginning of 2015 the following RA audit measure for combined biochemical control applied:
'Percentage of patients with all bone parameters within target range (Calcium/Phosphate/PTH)'
The RA guideline does not explicitly outline the target ranges to be used in the audit measure itself therefore the authors have interpreted this to include the target ranges suggested for each biochemical measure in the guideline. Therefore the combined audit measure comprised the following: phosphate 1.1-1.7 mmol/L, adjusted calcium 2.2-2.5 mmol/L and PTH 16-72 pmol/L. Please note this phosphate measure is discrepant with the preceding audit measure for phosphate alone (of ,1.7 mmol/L). This section presents only the audit measure of composite control, however data regarding attainment of each of the three components individually can be found in appendix 1.
There were combined biochemical results to assess mineral bone disease available from 57 HD and 52 PD centres, including 17,811 HD and 2,336 PD patients, from England, Wales and Northern Ireland in 2015. Table 8 .7 demonstrates the percentage of patients achieving results within the target range for none, one, two or all three bone mineral parameters, by centre for patients Methven/Perisanidou/Nicholas/Dawnay receiving HD and figure 8.6 shows the variation between centres in the proportion achieving control of all three parameters. Methven/Perisanidou/Nicholas/Dawnay Methven/Perisanidou/Nicholas/Dawnay figure 8 .14. Achievement of bicarbonate audit measures has not changed over the past decade for either modality. There has been a consistent difference between the modalities in the percentage with raised bicarbonate measures.
Discussion
A number of studies have demonstrated reduced dialysis patient survival with disordered calcium and phosphate levels [9, 10] as well as with inadequate simultaneous control of three MBD parameters [11] [12] [13] . This chapter presents the results of MBD management for established renal failure patients in the UK and demonstrates the overall ongoing improvement in achieving measures. However, the inter-and intra-centre variation in the control of MBD parameters remains a challenge. Some of these apparent differences may be as a result of confounding factors, rather than true differences in the quality of care. Analyses including adjustment for patient level factors will be undertaken in future years when the enhanced UKRR dataset is available from renal centres, such as comorbidity, phosphate binder, calcium mimetic and vitamin D analogue use and the dialysis dose and dialysate concentrations prescribed. In addition to adjusting for patient level factors (to account for case-mix) there are also centre level factors. The UKRR 7th Annual Report chapter 8 [14] discussed the problems related to variations in calcium and PTH measurements. It is an aspiration for future work also to integrate these into the analyses, such as assays used for the biochemical parameters and the local reference ranges. Overall data completeness was good for the biochemical variables presented in this chapter with some exceptions and data completeness has improved over the years. However, the UKRR will need to attain good data completeness for a host of other patient and centre level variables in order to undertake the adjusted analyses described.
Serum bicarbonate levels have not changed significantly compared with recent years, but a persistent fraction of HD patients still have raised bicarbonate levels. The UKRR has previously conducted a limited survey [15] into the possible underlying causes of serum bicarbonate variation. The study examined measures of sample processing and of dialysis treatment. It did not adjust for case-mix and was unable to detect any significant differences between centres. Studies have identified an increased risk of death stratified by a reduced predialysis serum bicarbonate level (,17 mmol/L) or with raised levels (.27 mmol/L) [16] [17] , as well as with raised dialysate bicarbonate concentrates [11] . Future analysis of management of acidosis will have to reexplore the factors associated with an increased trend in developing alkalosis in HD patients. This appendix includes analysis of the individual mineral bone measures that are included in the composite audit measure, namely adjusted calcium, phosphate and PTH within the recommended target ranges.
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Adjusted calcium
In 2015, the following Renal Association clinical practice guideline regarding calcium management was applicable:
Guideline 2.2 CKD-MBD: Serum calcium in dialysis patients (stage 5D) ' We suggest that serum calcium, adjusted for albumin concentration, should be maintained within the normal reference range for the laboratory used, measured before a "short-gap" dialysis session in haemodialysis patients. Ideally, adjusted serum calcium should be maintained between 2.2 and 2.5 mmol/L, with avoidance of hypercalcaemic episodes (2D)' [3] .
In 2015, data from 22,175 HD and 2,998 PD patients across the UK were available for serum adjusted calcium analysis. The data were 98.4% complete for HD patients and 98.7% complete for PD patients overall, although there was between centre variation (tables 8. 13, 8.15) . From 2004 to 2015 across UK centres, data completeness for serum adjusted calcium increased from 57.2% to 98.0% in HD patients and from 56.8% to 98.7% in PD patients.
London West and Belfast did not return locally adjusted calcium results for any patients, whilst Sunderland and Wirral returned adjusted calcium results for only a proportion of their patients. Hence these data are shown after adjustment using a generic formula that may not be applicable to the calcium and albumin methods used locally and may have over-or underestimated the adjusted calcium. These centres are served Methven/Perisanidou/Nicholas/Dawnay The proportion of hypocalcaemic patients in the UK was 10.6% for HD and 7.4% for PD (tables 8.14, 8.16). The proportion of hypercalcaemic patients in the UK was 10.1% for HD and 14.8% for PD (tables 8.14, 8.16). Figure 8 .16 presents the funnel plot of HD patients attaining adjusted calcium levels between 2.2 and 2.5 mmol/L in 2015. Five centre's results fell below the lower 99.9% confidence interval: Ulster, Edinburgh, Middlesbrough, London St Bartholomew's and London West. However, the London West data may be misleading since the centre failed to return locally adjusted calcium results. The percentage of HD patients with serum calcium within the reference range was significantly higher than the average (above the 99.9% confidence limit) in Newry, Colchester, Bradford, Exeter and Bristol. Figure 8 .18 presents the funnel plot of PD patients attaining the adjusted calcium levels between 2.2 and 2.5 mmol/L in 2015. Once corrected for centre size, no centre was significantly lower than the national average. There were three centres achieving a significantly higher percentage compared with the UK average: Truro, Leeds and Oxford.
Longitudinal changes in the control measures of serum adjusted calcium show improvements in the attained national standards. Hypocalcaemia in HD patients has declined since 2010, with no significant changes being observed in PD patients. In the same time period there has been a modest fall in hypercalcaemia in both modalities ( figure 8.19 ). Methven/Perisanidou/Nicholas/Dawnay ' We suggest that serum phosphate in dialysis patients, measured before a ''short-gap'' dialysis session in haemodialysis patients, should be maintained between 1.1 and 1.7 mmol/L (2C)' [3] For those receiving HD, 57.1% of patients achieved a phosphate level between 1.1-1.7 mmol/L, the guideline Methven/Perisanidou/Nicholas/Dawnay Funnel plots for HD patients with phosphate within the target range (1.1-1.7 mmol/L), show one centre (Birmingham Queen Elizabeth) attaining this standard in a significantly high proportion of patients (being above the 99.9% upper confidence interval following correction for centre size). In addition, two centres had achieved the serum phosphate control standard in a lower than expected proportion of patients (being below the lower 99.9% confidence interval): Portsmouth and London St Bartholomew's ( figure 8.21 ). Differences in outlier status can be seen when this guideline target measure is applied compared to the audit measure of phosphate ,1.7 mmol/L, namely fewer centres are found to be outliers.
The funnel plot for PD patients indicated that the control of phosphate levels was similar in all centres. No significant outliers were identified ( figure 8.23) .
Longitudinal analysis demonstrated a stable performance against the clinical guideline recommendation for those receiving HD and PD (figure 8.24).
Parathyroid hormone
At the beginning of 2015 the following RA guideline for PTH applied: Guideline 4.2.1 CKD-MBD: Target range of serum PTH in patients on dialysis ' We suggest that the target range for parathyroid hormone measured using an intact PTH assay should be between 2 and 9 times the upper limit of normal for the assay used (2C)' [3] .
PTH results from 18,880 HD patients and 2,412 PD patients from England, Northern Ireland and Wales In 2015, the proportion of HD patients with a PTH above the upper limit of the range (.72 pmol/L) was 18.8% and the proportion below the lower limit of the range (,16 pmol/L) was 24.4%.
The proportion of PD patients with PTH above the upper limit (.72 pmol/L) of the range was 13.9% and the proportion below the lower limit of the range (,16 pmol/L) was 22.6% (tables 8.20, 8.22 ).
There was significant variation by centre following unadjusted analyses for the proportion of patients below, within and above the range specified by the clinical performance measures. The funnel plot (figure 8.26) for HD patients showed above average achievement of the target range in Cardiff, Derby, Reading, London St Bartholomew's and London Royal Free and below average achievement for Liverpool Aintree, Exeter, Leicester, London Kings, London West and York. For PD patients (figure 8.28) Derby and Reading were above average achievement of the target range and there were no outliers below the 99.9% confidence interval for the target.
Longitudinal analysis of PTH control measures at the level of the three countries noted sustained reduction in the proportion of patients with low PTH levels 
